Vaccine Adjuvants Market worth $0.96 billion by 2029

The global vaccine adjuvants market is anticipated to reach USD 0.96 billion by 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%.
The global vaccine adjuvants market [https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr], valued at US$0.66 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$0.70 billion in 2024 and an impressive US$0.96 billion by 2029. The rise in global vaccination programs, rising demand for effective vaccines against emerging infectious diseases, and growing investments in vaccine and vaccine adjuvant research are some of the major factors propelling the growth of the market. Innovations in adjuvants, such as toll-like receptor agonists (TLRs), emulsions, and saponin-based compounds, and rising demand for veterinary vaccines are further likely to boost the adoption and, subsequently, growth of the market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Browse in-depth TOC on "Vaccine Adjuvants Market"

200 - Tables

45 - Figures

230 - Pages

The adjuvant emulsions segment is expected to have the dominant share of the vaccine adjuvants market

Based on product, the global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. In 2022, the adjuvant emulsions segment accounted for largest share of the vaccine adjuvants market. Increased use of adjuvant emulsions in the vaccine production is serving as driving factor for the growth of the adjuvant emulsions segment during the forecast period.

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market

The infectious diseases segment is the fastest growing segment and accounted for the largest share of the market in 2022. The large share of this segment can be attributed to rising demand for novel adjuvanted vaccines for infectious diseases. Rising focus on development of plant-based adjuvants is further likely to have positive impact on the segmental growth.

The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets on the region is driven by rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and increased adoption of adjuvanted vaccine among the patent population.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Key Market Players:

The vaccine adjuvants market is competitive, with a small number of players competing for market shares. Dynavax Technologies (US), GSK plc (UK), Croda International plc (UK), SEPPIC (France), Novavax (US), SPI Pharma (Associated British Foods plc) (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (Vertellus) (US), Merck KGaA (Germany) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

GSK Plc is one of the prominent players in vaccine adjuvants market. The company boasts strong research and development capabilities, a comprehensive adjuvant portfolio, and a strategic focus on innovative formulations. As a global leader in the vaccine adjuvants market, GSK leverages its extensive presence across North America, Europe, Asia, and emerging markets. This broad geographical reach enables GSK to address diverse healthcare needs and capitalize on regional growth opportunities in vaccine development and delivery.

SEPPIC, a leading player in the vaccine adjuvants market, is renowned for its innovative and versatile adjuvant solutions. Its key strengths include a diverse product portfolio featuring squalene-based emulsions, polymer-based adjuvants, and other advanced formulations tailored for both human and veterinary vaccines. The company has a robust geographic presence, with strong operations in Europe, North America, and emerging markets, allowing it to support global vaccine development initiatives. The company prioritizes R&D investments to develop next-generation adjuvants that improve immunogenicity and address unmet needs in human and veterinary vaccines. Its focus on the launch of new products further strengthens the market position. In October 2022, the company launched MONTANIDE GR 01, which is used to formulate veterinary oral vaccines by emulsification with aqueous antigens.

Croda International Plc. is a global leader in vaccine adjuvants, leveraging its extensive geographic presence and strong R&D capabilities. With operations spanning North America, Europe, and emerging markets in Asia Pacific and Latin America. The company offers a diverse portfolio of high-quality adjuvants, including novel technologies tailored to enhance vaccine efficacy and stability. Its advanced manufacturing facilities adhere to stringent regulatory standards, ensuring consistent supply. Croda's strategic choices in the vaccine adjuvants market reflect its commitment to innovation, sustainability, and global expansion.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vaccine-adjuvants-market-worth-096-billion-by-2029]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.